

Application Number: 10/602,456  
Balschmidt et al.  
Filed: June 23, 2003  
Attorney Docket No.: 6460.200-US  
Via Facsimile No.: 571-273-8300

### AMENDMENTS TO THE SPECIFICATION

Kindly replace the paragraph located on page 3, line 23 through line 27, of the specification as originally filed with the following replacement paragraph:

In another embodiment, the peptide is human insulin or an analogue thereof, or a derivative of human insulin or the human insulin analogue, such as human insulin, Asp(B28)-human insulin, Lys(B28) Pro(B29)-human insulin, Lys(B3) Glu(B29)-human insulin, N<sup>ε</sup>B29-tetradecanoyl des (B30)-human insulin, Gly(A21) Arg(B31) Arg(B32)-human insulin or N<sup>ε</sup>B29-lithocholyl-γ-glutamyl des (B30)-human insulin. As used herein, Lys(B28) refers to a lysine residue located at position 28 of the B chain of human insulin. Likewise, Gly(A21) refers to a glycine residue located at position 21 of the A chain of human insulin. Therefore, as used herein Gly(A21) Arg(B31) Arg(B32)-human insulin refers to human insulin in which a glycine residue is located at position 21 of the A chain, and two additional arginine residues are located on the B chain at positions 31 and 32.